Sequenom (WPKN 932193) - Aussichten und Meinungen - 500 Beiträge pro Seite

[The Trader]

Hallo,

Es wäre schön, wenn Ihr Euere Aussichten und Meinungen zu Sequenom in diesem Thread posten würdet.

Danke !!!

The Trader

[db18]

Hier neue Meldungen von Sequenom. Werden am Markt wohl nicht positiv aufgenommen. Die Diskussion hier ist auch völlig zum Erliegen gekommen.

Wenn das so weiter geht, sieht SQNM bald wieder Tiefstkurse.

Wäre für fundierte Meinungen und Einschätzungen dankbar.


Gruß Joachim


SAN DIEGO, June 19 /PRNewswire/ -- SEQUENOM(TM), Inc. (Nasdaq: SQNM - news) today provided business strategy and financial guidance related to its proposed merger with Gemini Genomics, announced May 29, 2001. The combined company, which will operate under the name SEQUENOM and its existing ticker symbol SQNM, represents what the companies believe to be the industry`s largest disease gene identification initiative. Maximizing the value of its MassARRAY(TM) business and disease gene discoveries, SEQUENOM will operate SEQUENOM Genomics and SEQUENOM Biotherapeutics.
Company Structure
SEQUENOM Genomics will focus on MassARRAY systems and consumables sales, MassARRAY-based services provided to the Company`s collaborators, and disease gene association licensing and validation programs. Based on the performance of MassARRAY technology and a proprietary population genetics approach, SEQUENOM identifies genes that affect the health of large portions of the human population. SEQUENOM Genomics is executing a program to identify approximately 400 genes with significant impact on human health. The merger with Gemini will substantially accelerate the Company`s ability to characterize the association of candidate disease genes to major common diseases.
SEQUENOM Biotherapeutics will apply technologies to transition human disease genes into drugs and diagnostics, leveraging the value of candidate disease genes identified by SEQUENOM Genomics. SEQUENOM Biotherapeutics will accelerate and expand Gemini`s existing target discovery activities, including functional genomic and computational biology approaches. Additional investments will be made for resources in areas such as target and lead validation, drug development and clinical validation. Partnering opportunities may exist at any point along this process, with a focus on licensing later stage, higher value discoveries. SEQUENOM Biotherapeutics will also seek strategic partners to leverage additional value from Gemini`s extensive clinical resources.
Financial Projections
Financial benefits from internal development of diagnostic and therapeutic products are expected after the fiscal year ending December 31, 2002, but are difficult to predict at this stage. However, SEQUENOM expects enhanced near-term opportunities in commercializing validated human disease-related genes and diagnostics and securing additional collaborations with biotechnology and pharmaceutical companies.
Revenue expectations for 2001, before deduction of the cost of goods sold, remain at $30 million, as previously stated by SEQUENOM during its first quarter financial results webcast. This includes approximately $20 million in MassARRAY systems and consumables sales and $10 million in genomics services provided to the Company`s collaborators. Revenues for 2002, before the deduction of the cost of goods sold, are expected to be approximately $60 million. This includes $45 million in MassARRAY products and services and $15 million in gene license and biotherapeutic service revenues.
Research and development expenses are currently expected to be approximately $30 million for 2001 and approximately $45 million for 2002. SEQUENOM and Gemini have a current combined headcount of approximately 345 employees. The combined company expects to end the fiscal year 2001 with approximately 300 employees. Employee headcount is expected to increase to approximately 400 people by the end of fiscal year 2002.
SEQUENOM and Gemini ended March 31, 2001 with a combined cash position of approximately $208 million. Net cash used for operating activities is expected to be approximately $36 million for the remainder of 2001. SEQUENOM also anticipates merger integration expenses of approximately $22 million. These expenses include transaction, restructuring and associated tax liability costs. SEQUENOM estimates that the consolidated cash position will be approximately $150 million at the end of fiscal year 2001. The Company expects cash use of approximately $50 million for 2002. The newly formed SEQUENOM Biotherapeutics business is expected to utilize approximately $15 million or 30% of the 2002 cash burn. Break even is not likely to occur for the next several years.
``We are executing on a business model that capitalizes on the immediate value of genes associated with major diseases and their downstream value through diagnostic and therapeutic product development,`` said Toni Schuh, Ph.D., SEQUENOM`s President and Chief Executive Officer.
``By mid 2002 we intend to expand the leading market position of the MassARRAY product line for large-scale genotyping and screen all human genes with regard to their overall population impact. We also expect to identify a subset of 400 high value candidate disease genes. To date, as a combined company, we hold a portfolio of more than 115 such candidate disease genes. We use a filtering strategy, our population genetics approach, to identify the disease genes that indicate an impact on large portions of the total human population. Also important to this strategy is that we determine the impact of a gene on human health upfront. The result is a subset of high value disease genes on which to focus drug development efforts. We believe this quality, rather than quantity approach to drug target discovery will result in leads with significant market potential.``...

[Frau_Breule]

Verkaufen



mfg Breule